摘要
软组织肉瘤(softtissuesarcomas, STS )是一类起源于结缔组织(除骨与软骨)的恶性肿瘤,发病率大约(1.28~1.72 )/10万,约占成人恶性肿瘤的1%[1]。STS具有高度异质性,包括19种组织类型及50多个不同亚型,高级别软组织肉瘤以脂肪肉瘤(liposarcoma )和多形性未分化肉瘤(undifTerentiatedpleomorphicsarcoma, UPS)最多见[2]。
Soft tissue sarcomas(STS)are a group of rare and highly heterogeneous neoplasms with mesenchymal origin.The main management for STS is surgical resection but with a high rate of recurrence and metastasis.The first-line chemotherapy for advanced STS is doxorubicin or combination with ifosfamide.Now,molecular targeted therapy becomes a new approach for STS.Anlotinib,a novel tyrosine kinase inhibitor,showed antitumor activity in several STS entities.But for advanced progressive STS,targeted therapy need to combine with local intervention,such as argon-helium cryosurgery,local radiotherapy,interventional embolization,et al.Patients should have cytoreductive surgery if they have operation indication.The initial outcomes of clinical trials of immunotherapy also showed a satisfactory efficacy in STS.Despite the advances in the above therapies,novel therapeutics are needed.We should continuously explore and improve the multidisciplinary therapy of STS.
作者
王臻
WANG Zhen(Department of Orthopaedics,the Air Force Military Medical University,Xi'An,Shaanxi,710032,China)
出处
《中国骨与关节杂志》
CAS
2019年第1期1-2,共2页
Chinese Journal of Bone and Joint
关键词
晚期
软组织肉瘤
治疗
Advanced
Softtissuesarcoma
Treatment
